Investors
PTX is a clinical stage life-science company focused on the development of therapies that prevent the toxic consequences of chemotherapy. PTX has multiple product candidates in development that are based on molecules with well-known safety profiles. The company is raising a Series A round to complete the Phase 1b clinical study and enter Phase 2 for PTX-078 and Complete the Phase 2 clinical study for PTX-501. The management team has worked together in successful startups and each member has decades of experience in product development and gaining FDA approvals.
About PTX-078
Cancer patients oftentimes undergo chemotherapy with platinum-based drugs such as cisplatin, which is the most effective, most commonly used, and most toxic chemotherapy agent. Oncologists have major concerns about the loss of hearing and kidney function. They monitor the patient for signs of toxicity, which is the primary cause of decreasing the dose and duration of treatment, and thus potentially decreasing its effectiveness. PTX-078 is designed to prevent nephrotoxicity and ototoxicity in patients undergoing platinum-based chemotherapy and may allow for a higher dose and longer duration of treatment. The market opportunity for PTX-078 is $2.8 billion in the United States and over $5 billion worldwide.
About PTX-501
Patients that undergo intermittent dialysis may experience muscle cramps due to the rapid withdrawal of fluid, which is the general purpose of the procedure. However, these muscle cramps can be painful and may cause the patient to prematurely discontinue therapy. PTX-501 is designed to prevent muscle cramps in patients undergoing dialysis. PTX is conducting a Phase 1b study in Australia. The market opportunity for our follow-on product, PTX-501, is $454 million.